Descripción de la empresa
NewGenIvf Group Limited operates as an investment holding company focused on the provision of assisted reproductive services, facilitating fertility treatments for couples and individuals across Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The enterprise functions within the healthcare sector, specifically categorized under the medical care facilities industry, which implies a direct engagement with essential medical services and regulatory compliance in reproductive health. As of the latest reporting period, the company maintains a market capitalization of $1.21M and reports an annual revenue of $4.73M, while the specific employee count is listed as not available. These valuation and revenue figures indicate that the entity functions as a micro-cap enterprise with a relatively small market footprint compared to large-cap healthcare peers, suggesting a niche operational scale within the global fertility treatment landscape.
Salud financiera
The company reported a trailing twelve-month revenue of $4.73M and a net income of $9.88M, while simultaneously reporting an EBITDA of -$10,538,352, revealing a significant structural divergence between accounting profitability and cash generation from operations. The substantial gap where net income is positive while EBITDA is deeply negative indicates that the company likely records substantial non-cash expenses, such as significant depreciation and amortization, which reduce EBITDA but are not reflected in the net income calculation under current accounting standards. Free cash flow stands at -$11,179,275, signaling that the company is currently consuming cash reserves to fund its operations or capital expenditures, thereby limiting immediate financial flexibility and requiring external financing or retained earnings to sustain liquidity. The gross margin is recorded at 20.2%, suggesting that after covering the direct costs of providing fertility treatments, the company retains a moderate portion of revenue as contribution margin. However, the operating margin of -349.1% and the profit margin of 209.0% present conflicting indicators that necessitate close examination of the specific accounting adjustments made to arrive at net income versus operating expenses. The balance sheet shows cash holdings of $1.30M against total debt of $4.87M, resulting in a debt-to-equity ratio of 18.74, which characterizes a highly leveraged position where liabilities significantly exceed equity capitalization. Despite the debt load, the current ratio of 3.12 suggests robust short-term liquidity, indicating that current assets are more than three times current liabilities, providing a buffer to meet immediate obligations. Return on Equity is an unusually high 79.4%, while Return on Assets is -36.9%, further illustrating the complex interplay between high leverage, non-cash accounting charges, and the specific methodology used to calculate these return metrics.
Evaluación de valoración
The trailing P/E ratio is listed at 0.06 and the forward P/E is 0.23, though these low figures must be interpreted with caution given the reported negative EBITDA and the discrepancy between positive net income and negative operating cash flow. The price-to-book ratio is 0.00, indicating that the market valuation is effectively zero relative to the company's book value, which often occurs in micro-cap situations where book value calculations do not reflect the true economic reality or where equity is heavily diluted. The price-to-sales ratio stands at 0.26, suggesting the market values the company at a fraction of its revenue, while the EV/EBITDA metric is listed as N/A due to the negative earnings before interest, taxes, depreciation, and amortization. Over the past year, the stock has traded between a 52-week low of $1.52 and a 52-week high of $1839.00, highlighting extreme volatility in a security with a market cap of $1.21M. The beta value is listed as N/A, meaning there is insufficient data to calculate the stock's sensitivity to broader market movements relative to the benchmark index. These alternative valuation metrics collectively suggest a high-risk profile where traditional valuation multiples may not be applicable in their standard form.
Growth & Income
Revenue growth year-over-year is recorded at 11.9%, while earnings growth year-over-year is listed as N/A due to the irregularity in earnings presentation or the specific accounting adjustments affecting the reported net income. The divergence between positive revenue growth and the lack of a standard earnings growth figure implies that top-line expansion is occurring, yet the bottom line is heavily influenced by non-operating factors or significant one-time accounting events rather than core operational scaling. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that any generated net income is reinvested back into the business or used to service debt rather than distributed to shareholders. Consequently, the overall growth and income profile is defined by capital appreciation potential driven by revenue expansion rather than income generation through dividends or stable earnings growth.